It comes in a syringe or in a self-injector pen. It can be given by the patient at home or in the office. No tests are usually required to use dupilumab (Dupixent). Of course, you should follow ...

Dupixent is available in Japan in a 300 mg dose as a pre-filled syringe or pre-filled pen and is now available for COPD ... More than 1,000,000 patients are being treated with Dupixent globally.1 ...

Dupixent is available in Japan in a 300 mg dose as a pre-filled syringe or pre-filled pen and is now available ... treated with Dupixent globally.1 Dupilumab is being jointly developed by ...

The FDA has approved the popular drug Dupixent (generic name, dupilumab) for adults and kids 12 and up with chronic spontaneous urticaria (CSU), a long-lasting itchy skin condition, when regular ...

The green light for the pre-filled, single-use pen version of Tezspire (tezepelumab ... such as Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's IL-5 inhibitor Fasenra ...

The US Food and Drug Administration (FDA) has approved dupilumab for the treatment of chronic spontaneous urticaria (CSU) in patients aged 12 years and older who “remain symptomatic despite H1 ...

In a post-hoc analysis, dupilumab improved symptoms of atopic dermatitis (AD) in young children ages 6 months to 5 years. Youngsters with associated comorbidities such as asthma, allergic rhinitis ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab was approved for treatment of chronic spontaneous urticaria in patients aged 12 years and older.

Dupilumab is now approved for CSU patients aged 12+ not controlled by H1 antihistamines, targeting IL-4 and IL-13 pathways. Phase 3 trials showed significant reductions in itch and urticaria ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with ...

In phase 3 trials, dupilumab significantly reduced itch and hives compared with placebo. The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult and ...

Sanofi and Regeneron's fully human monoclonal antibody Dupixent (dupilumab) has gained approval from the US Food and Drug Administration (FDA) for treating chronic spontaneous urticaria (CSU ...